A pharmaceutical composition for preventing and treating ischemic stroke-related diseases, its preparation method and application
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for ischemic stroke and composition, which is applied in the field of medicine, can solve problems such as the lack of clear active ingredients of compound Xueshuantong preparations, and achieve the effect of improving auricle microcirculation, strong controllability, and clear components
Active Publication Date: 2016-07-27
GUANGDONG ZHONGSHENG PHARMA
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] The purpose of the present invention is to provide a pharmaceutical composition for preventing and treating diseases related to ischemic stroke, aiming to solve the problem that the active ingredients of compound Xueshuantong preparation are not clear enough
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0026] The preparation of embodiment one pharmaceutical composition
[0027] Weigh 27g notoginsenoside R 1 , 69g ginsenoside Rg 1 , 62g ginsenoside Rb 1, 21g ginsenoside Re, 0.4g astragaloside IV, 0.038g calycosin-7-O-β-D-glucopyranoside, 0.36g harpagoside, 0.039g cinnamic acid, 10g salvianolic acid B, 0.24g crypto Tanshinone and 0.28g tanshinone IIA were mixed uniformly to obtain a pharmaceutical composition.
Embodiment 2
[0028] The preparation of embodiment two pharmaceutical compositions
[0029] Weigh 15g notoginsenoside R 1 , 52g ginsenoside Rg 1 , 46g ginsenoside Rb 1 , 17g ginsenoside Re, 1.1g astragaloside IV, 0.06g calycosin-7-O-β-D-glucopyranoside, 0.18g harpagoside, 0.022g cinnamic acid, 7.2g salvianolic acid B, 0.47g Cryptotanshinone and 0.5 tanshinone IIA are mixed evenly to obtain a pharmaceutical composition.
Embodiment 3
[0030] The preparation of embodiment three pharmaceutical compositions
[0031] Weigh 21g notoginsenoside R 1 , 58g ginsenoside Rg 1 , 52g ginsenoside Rb 1 , 17g ginsenoside Re, 1.1g astragaloside IV, 0.07g calycosin-7-O-β-D-glucopyranoside, 0.48g harpagoside, 0.042g cinnamic acid, 7.7g salvianolic acid B, 0.47g Cryptotanshinone, 0.49g of tanshinone IIA and 0.51g of tanshinone I were mixed uniformly to obtain a pharmaceutical composition.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention is applicable to the technical field of medicine, and provides a pharmaceutical composition for preventing and treating diseases related to ischemic stroke, comprising 1.0 to 3.5 parts of notoginsenoside R 1 , 4.0 to 7.5 parts of ginsenoside Rg 1 , 3.5 to 7.5 parts of ginsenoside Rb 1 , 1.0 to 3.0 parts of ginsenoside Re, 0.03 to 0.15 parts of astragaloside IV, 0.002 to 0.010 parts of calycosin-7-O-β-D-glucopyranoside, 0.01 to 0.10 parts of harpagoside, and 0.002 to 0.010 parts of cinnamon acid, 0.45-1.5 parts of salvianolic acid B, 0.02-0.10 parts of cryptotanshinone and 0.02-0.10 parts of tanshinone IIA. The pharmaceutical composition provided by the invention has the functions of promoting blood circulation, removing blood stasis, nourishing qi and nourishing yin, can prevent and treat diseases related to ischemic stroke, and overcomes the shortcomings of traditional compound Chinese medicine preparations such as complicated components.
Description
technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a pharmaceutical composition for preventing and treating diseases related to ischemic stroke, a preparation method and application thereof. Background technique [0002] Compound Xueshuantong preparation is a pure traditional Chinese medicine preparation made from four medicinal materials of Sanqi, Danshen, Astragalus, and Scrophulariae. It has the functions of promoting blood circulation and removing blood stasis, nourishing qi and nourishing yin, dilating blood vessels, and improving blood circulation and microcirculation. Compound Xueshuantong preparations include Fufang Xueshuantong Capsules, Compound Xueshuantong Tablets, Compound Xueshuantong Soft Capsules, Compound Xueshuantong Granules, and Compound Xueshuantong Dropping Pills. The key for compound Xueshuantong preparation to exert its functions of promoting blood circulation, removing blood stasis, nourishin...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more